Candida auris, an emerging pathogen – Challenge in the survival of microprimies

Ramya, Gurujala Mahadeva; Balakrishnan, Umamaheswari; Chandrasekaran, Ashok; Abiramalatha, Thangaraj; Amboiram, Prakash; Sekar, Uma; Devi, Usha

doi:10.1016/j.ijmmb.2021.03.025

Cited by 6 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the European CDC survey, 10 European countries have encountered patients colonized or infected with C. auris [ 70 ]. At present, 256 pediatric incidences have been reported from Venezuela, Colombia, Pakistan, Republic of Korea, India, Oman, Iran, Italy and the Gauteng province in South Africa [ 16 , 17 , 20 , 21 , 22 , 23 , 24 , 25 , 29 , 30 , 31 , 32 , 34 , 48 ] ( Figure 1 ). The majority of pediatric incidences were reported from South America (114/256, 45%) and South Asia (67/256, 26%), in several nosocomial outbreaks.…”

Section: The Epidemiology Of C Aurismentioning

confidence: 99%

“…According to the 22 publications of C. auris infection, comprising 256 children [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ], reviewed herein, the most common type of invasive infection was bloodstream infection (94%, 194/206 patients with available data on the infection site) ( Table 3 and Table S1 ). The duration of candidemia was not reported in most studies and was available for only seven patients; the duration ranged between 7 and 11 days [ 16 , 20 , 36 ].…”

Section: Clinical Spectrum Of C Auris Infectionmentioning

confidence: 99%

“…The duration of candidemia was not reported in most studies and was available for only seven patients; the duration ranged between 7 and 11 days [ 16 , 20 , 36 ]. Other sites of infection included meningitis, endocarditis, intravascular infection, peritonitis, urinary tract infection, skin abscess and otitis [ 16 , 25 , 34 ]. The associated mortality rates reported ranged from 0%, to as high as 80%.…”

Section: Clinical Spectrum Of C Auris Infectionmentioning

confidence: 99%

“…Antifungal treatment varied between studies. A number of studies treated invasive infections with antifungal combination [ 16 , 22 , 25 , 34 ]. Due to the small number of patients, conclusions could not be drawn regarding differences in mortality rates according to antifungal regimens.…”

Section: Clinical Spectrum Of C Auris Infectionmentioning

confidence: 99%

“…Publications were reviewed and selected based on their quality and pertinence. Following exclusion of suspected repetitive studies, the search yielded 23 publications that reported C. auris incidents in children [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ]. Twelve publications included both adult and pediatric patients [ 17 , 19 , 20 , 23 , 24 , 26 , 27 , 28 , 32 , 35 , 36 , 37 ]; of them, one did not provide specific details of the pediatric patients and was excluded [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics of Candida auris, with a Focus on Children

Ashkenazi‐Hoffnung

Danziger

2023

JoF

View full text Add to dashboard Cite

During the past decade, Candida auris emerged across the world, causing nosocomial outbreaks in both pediatric and adult populations, particularly in intensive care settings. We reviewed the epidemiological trends and the clinical and microbiological characteristics of C. auris infection, focusing on the pediatric population. The review is based on 22 studies, which included about 250 pediatric patients with C. auris infection, across multiple countries; neonates and premature babies were the predominant pediatric patient group affected. The most common type of infection reported was bloodstream infection, which was associated with exceptionally high mortality rates. Antifungal treatment varied widely between the patients; this signifies a serious knowledge gap that should be addressed in future research. Advances in molecular diagnostic methods for rapid and accurate identification and for detection of resistance may prove especially valuable in future outbreak situations, as well as the development of investigational antifungals. However, the new reality of a highly resistant and difficult-to-treat pathogen calls for preparedness of all aspects of patient care. This spans from laboratory readiness, to raising awareness among epidemiologists and clinicians for global collaborative efforts to improve patient care and limit the spread of C. auris.

show abstract

Section: The Epidemiology Of C Aurismentioning

confidence: 99%

Section: Clinical Spectrum Of C Auris Infectionmentioning

confidence: 99%

Section: Clinical Spectrum Of C Auris Infectionmentioning

confidence: 99%

Section: Clinical Spectrum Of C Auris Infectionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics of Candida auris, with a Focus on Children

Ashkenazi‐Hoffnung

Danziger

2023

JoF

View full text Add to dashboard Cite

show abstract

Candida auris as the Predominant Species Causing Invasive Candidiasis in Neonates and Children

et al. 2023

View full text Add to dashboard Cite

The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England

Jones,

Neill,

Borman

et al. 2024

Journal of Medical Microbiology

View full text Add to dashboard Cite

The emergent fungal pathogen Candida auris is increasingly recognised as an important cause of healthcare-associated infections globally. It is highly transmissible, adaptable, and persistent, resulting in an organism with significant outbreak potential that risks devastating consequences. Progress in the ability to identify C. auris in clinical specimens is encouraging, but laboratory diagnostic capacity and surveillance systems are lacking in many countries. Intrinsic resistance to commonly used antifungals, combined with the ability to rapidly acquire resistance to therapy, substantially restricts treatment options and novel agents are desperately needed. Despite this, outbreaks can be interrupted, and mortality avoided or minimised, through the application of rigorous infection prevention and control measures with an increasing evidence base. This review provides an update on epidemiology, the impact of the COVID-19 pandemic, risk factors, identification and typing, resistance profiles, treatment, detection of colonisation, and infection prevention and control measures for C. auris. This review has informed a planned 2024 update to the United Kingdom Health Security Agency (UKHSA) guidance on the laboratory investigation, management, and infection prevention and control of Candida auris. A multidisciplinary response is needed to control C. auris transmission in a healthcare setting and should emphasise outbreak preparedness and response, rapid contact tracing and isolation or cohorting of patients and staff, strict hand hygiene and other infection prevention and control measures, dedicated or single-use equipment, appropriate disinfection, and effective communication concerning patient transfers and discharge.

show abstract

Candida auris, an emerging pathogen – Challenge in the survival of microprimies

Cited by 6 publications

References 9 publications

Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics of Candida auris, with a Focus on Children

Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics of Candida auris, with a Focus on Children

Candida auris as the Predominant Species Causing Invasive Candidiasis in Neonates and Children

The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England

Contact Info

Product

Resources

About